GENinCode PLC
GENI
Company Profile
- Business description- GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom. 
- Contact- Oxford Science Park 
 John Eccles House, Robert Robertson Avenue
 OxfordOX4 4GP
 GBR- T: +44 1865676125 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Diagnostics & Research - Fiscal Year End- 31 December 2025 - Employees- 36 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,127.05 | 30.24 | -0.37% | 
| DAX 40 | 24,003.65 | 115.24 | -0.48% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,729.47 | 30.59 | -0.31% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,822.34 | 0.00 | 0.00% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |